secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001193125-23-265168
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst reports FDA approval of AGAMREE for DMD; expects Q1 2024 launch
------------------------------------------------------------------------

- Santhera received FDA approval for AGAMREE (vamorolone) oral suspension 40 mg/mL for DMD in patients aged 2+.
- Catalyst holds exclusive North American license; NDA transfer from Santhera to Catalyst is prompt.
- Catalyst expects to commercially launch AGAMREE in Q1 2024 with a patient assistance program.
- AGAMREE has orphan drug exclusivity (7 years) and patent protection potentially until 2040.
- Approval based on Phase 2b VISION-DMD study and open-label extension data up to 48 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523265168/0001193125-23-265168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523265168/d577328d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-265168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer